Diabetes News You Can Use

Finerenone reduces diabetes risk with heart failure

Finerenone lowers the risk of new-onset diabetes in patients with heart failure and mildly reduced or preserved ejection fraction, according to a study in The Lancet Diabetes & Endocrinology. The FINEARTS-HF trial showed that over a median follow-up of 31.3 months, finerenone reduced the incidence of new-onset diabetes by 24% compared with placebo.

 Full Story: Endocrinology Advisor (2/3)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Plant-based meat alternatives may lower cholesterol

A systematic review in The American Journal of Clinical Nutrition indicates that short-term consumption of plant-based meat alternatives can significantly reduce total and LDL cholesterol. The study, which analyzed data from seven randomized controlled trials, found a 6% decrease in total cholesterol and a 12% decrease in LDL cholesterol among adults without cardiovascular disease.

 Full Story: Medical News Today (2/2)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Metformin reduces diabetes risk

A study in Diabetes Care found that daily metformin reduces the incidence of type 2 diabetes among individuals with metabolic syndrome. The Metformin and Dietary Restriction to Prevent Age-Related Morbid Events in People With Metabolic Syndrome trial found that participants taking metformin with or without a Mediterranean diet had a lower incidence of diabetes compared with those taking a placebo.

 Full Story: Healio (free registration) (1/30)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Report: Heart disease is still leading cause of death

Heart disease continues to be the leading cause of death in the US, driven by rising rates of hypertension, obesity and other risk factors, according to the American Heart Association’s 2025 Heart Disease and Stroke Statistics. Cardiovascular disease claims more lives than cancer and accidental deaths combined. The report noted almost 47% of adults have hypertension, 57% have type 2 diabetes or prediabetes and more than 72% have an unhealthy weight.

 Full Story: Medscape (1/28)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Semaglutide approved for patients with diabetes, kidney disease

The FDA approved semaglutide to reduce the risk of worsening kidney disease, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to Novo Nordisk. The approval affects 0.5-mg, 1-mg and 2-mg doses of semaglutide.

 Full Story: MedPage Today (free registration) (1/28)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Bariatric surgery lowers liver risk in MASH cirrhosis

An observational study in Nature Medicine found bariatric surgery lowers the long-term risk of liver decompensation and major adverse liver outcomes in patients with compensated MASH-related cirrhosis. The 15-year cumulative incidence of major adverse liver outcomes was 21% for surgical patients versus 46% for nonsurgical patients.

Full Story: MedPage Today (free registration) (1/27)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Diabetes more prevalent among adults with disabilities

Adults with functional disabilities have a higher prevalence of diabetes, according to a CDC study published in Diabetes Care. The study, using data from the 2021-2022 National Health Interview Survey, found that 11.2% of adults with disabilities have diabetes, compared with 5.8% of those without disabilities.

 Full Story: Endocrinology Advisor (1/27)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Sex and medication use may affect semaglutide initiation

A study in JAMA Network Open found that only 2% of more than 97,000 commercially insured adults with obesity but not diabetes start semaglutide within six months of diagnosis. Factors such as female sex, insurance type and antidepressant use significantly influence initiation. The study highlights potential inequities in access to the medication.

 Full Story: HCPLive Network (1/21)  

 
 
 
 
 
 
 
 
 
 
 
 
 
 

Intensive glucose control lowers heart, mortality risk

A post hoc analysis of trial data, published in Diabetes Care, indicates that intensive glucose control reduces mortality and cardiovascular risk among patients with type 2 diabetes, regardless of age at diagnosis or disease duration. However, the risk of hypoglycemia increased significantly across all subgroups.

 Full Story: Healio (free registration) (1/21)  

 
 
 
 
 
 
 
 
 
 
 
 
 

GLP-1 receptor agonists show diverse health outcomes

A study in Nature Medicine using Veterans Affairs data has found that GLP-1 receptor agonists reduce risks for 42 health outcomes but increase risks for 19 others. The study was based on data for nearly 2 million individuals.

 Full Story: MedPage Today (free registration) (1/20)